A Paclitaxel-Eluting Stent Found Inferior to an Everolimus-Eluting Stent in Diabetes Patients

These findings might raise questions about studies comparing revascularization strategies with first-generation stents in diabetes patients.

In general, paclitaxel-eluting stents (PES) have been inferior to “limus-eluting” stents, but the results in diabetes mellitus (DM) patients have been more conflicting. In this manufacturer-funded, randomized study, investigators in India compared a PES with a current-generation, everolimus-eluting stent (EES) in 1830 patients with DM and coronary artery disease.

Insulin-requiring DM was present in 40% of patients, and the mean duration of diabetes was 6.3 years. At 1-year follow-up, the rate of target-vessel failure was inferior with PES compared with EES (5.6% vs. 2.9%). Most secondary endpoints also significantly favored EES, including the rate of myocardial infarction (1.2% vs. 3.2% with PES) and stent thrombosis (0.4% vs. 2.1%). The rat…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)